Pregabalin was blocked from the market by Pfizer.
 It was announced in October 2018, that Pregabalin would become reclassified as a class C controlled substance from April 2019
The World Federation of Biological Psychiatry recommends pregabalin as one of several first line agents for the treatment of generalized anxiety disorder, but recommends other agents such as SSRIs as first line treatment for obsessivecompulsive disorder and post-traumatic stress disorder (PTSD)

